Incyte Corp. (INCY)
125.35
-2.39
(-1.87%)
USD |
NASDAQ |
Aug 28, 11:58
Incyte Cash from Operations (Quarterly) : 507.66M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 507.66M |
| March 31, 2026 | 369.35M |
| December 31, 2025 | 543.30M |
| September 30, 2025 | 559.39M |
| June 30, 2025 | 44.74M |
| March 31, 2025 | 266.07M |
| December 31, 2024 | 381.22M |
| September 30, 2024 | 310.87M |
| June 30, 2024 | -575.56M |
| March 31, 2024 | 218.81M |
| December 31, 2023 | 147.73M |
| September 30, 2023 | 147.84M |
| June 30, 2023 | 306.53M |
| March 31, 2023 | -105.60M |
| December 31, 2022 | 283.66M |
| September 30, 2022 | 296.38M |
| June 30, 2022 | 174.16M |
| March 31, 2022 | 215.74M |
| December 31, 2021 | 115.35M |
| September 30, 2021 | 255.10M |
| June 30, 2021 | 172.94M |
| March 31, 2021 | 206.10M |
| December 31, 2020 | 107.32M |
| September 30, 2020 | 182.12M |
| June 30, 2020 | 269.38M |
| Date | Value |
|---|---|
| March 31, 2020 | -683.42M |
| December 31, 2019 | 131.62M |
| September 30, 2019 | 270.42M |
| June 30, 2019 | 152.96M |
| March 31, 2019 | 155.66M |
| December 31, 2018 | 83.84M |
| September 30, 2018 | 199.15M |
| June 30, 2018 | 32.40M |
| March 31, 2018 | 20.84M |
| December 31, 2017 | -80.33M |
| September 30, 2017 | 53.12M |
| June 30, 2017 | 115.96M |
| March 31, 2017 | -181.74M |
| December 31, 2016 | 94.38M |
| September 30, 2016 | 95.27M |
| June 30, 2016 | 17.57M |
| March 31, 2016 | 97.54M |
| December 31, 2015 | 70.01M |
| September 30, 2015 | 7.723M |
| June 30, 2015 | 13.39M |
| March 31, 2015 | -4.586M |
| December 31, 2014 | 45.10M |
| September 30, 2014 | 27.41M |
| June 30, 2014 | -14.56M |
| March 31, 2014 | -31.96M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Mirum Pharmaceuticals, Inc. | -44.25M |
| Regeneron Pharmaceuticals, Inc. | 813.00M |
| BioMarin Pharmaceutical, Inc. | 168.11M |
| Eli Lilly & Co. | 10.69B |
| Biogen, Inc. | 448.90M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -51.79M |
| Cash from Financing (Quarterly) | 65.46M |
| Free Cash Flow | 1.890B |
| Free Cash Flow Per Share (Quarterly) | 2.378 |
| Free Cash Flow to Equity (Quarterly) | 496.41M |
| Free Cash Flow to Firm (Quarterly) | 495.70M |
| Free Cash Flow Yield | 7.35% |